Patent intelligence · US
US 12343381
Dosage regimen for pegylated interferon
Dosage regimen for pegylated interferon
Patent details — US 12343381
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 1, 2025
- Expiration
- Jun 26, 2045
- Applicant
- PHARMAESSENTIA CORPORATION
- Claims
- 22
- CPC classes
- A61K, A61K38/21, A61K38/212, A61K47/60
Quick answer
US 12343381 (Dosage regimen for pegylated interferon) is held by PHARMAESSENTIA CORPORATION. Status: granted. Granted Jul 1, 2025. Expires Jun 26, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PHARMAESSENTIA CORPORATION
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K38/21, A61K38/212, A61K47/60, A61P, A61P19/00
More from PHARMAESSENTIA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 12343381?
US 12343381 (Dosage regimen for pegylated interferon) is held by PHARMAESSENTIA CORPORATION. Status: granted. Granted Jul 1, 2025. Expires Jun 26, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12343381?
PHARMAESSENTIA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 12343381 expire?
Our index shows an expiration date of Jun 26, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.